Synapse
⌘+K
Sign In
Sign Up for Free
Synapse
Sign In
Sign Up for Free
Home
Communities
Explore
More
Language
English
English
Roche (Portugal)
h-index: 13
Total citations: 826
Total papers: 73
Homepage:
http://www.roche.pt/
Recent papers from Roche (Portugal)
Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial
Nature Medicine · 2026
Evaluation of a Tumor-Informed Molecular Residual Disease Assay in Early Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy, With or Without Atezolizumab
JCO Precision Oncology · 2026
Real-World Outcomes of Faricimab in Patients with Highly Refractory Neovascular Age-Related Macular Degeneration in Portugal: The REVEAL Study
Ophthalmology and Therapy · 2026
Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancer
The Breast · 2026
Abstract CT013: Whole-exome sequencing tumor-informed circulating tumor DNA detection after completion of neoadjuvant treatment predicts non-pCR and distant recurrence in patients with early triple-negative breast cancer (TNBC) — Results from a sub-study of the NSABP B-59/GBG-96-GeparDouze Trial
Cancer Research · 2026
Treatment patterns and clinical outcomes according to PD-L1 status in >2000 patients with early-stage or metastatic triple-negative breast cancer treated in the real-world setting: VANESSA study results
The Breast · 2026
Real‐world prevalence of PD ‐ L1 positivity in early‐stage/metastatic triple‐negative breast cancer: primary results and pathology insights from the global retrospective observational VANESSA study
Histopathology · 2026
Abstract RF3-02: Gene Expression-based Subtyping of Early Triple-Negative Breast Cancer (TNBC) for Prediction of Response to Neoadjuvant Immune-chemotherapy in the NSABP B-59/GBG-96-GeparDouze Trial
Clinical Cancer Research · 2026
Abstract RF2-06: Impact of Immune Checkpoint Inhibition (CPI) on Fertility in Young Women with Early Triple-Negative Breast Cancer (TNBC) receiving neoadjuvant Chemotherapy (NACT): A Prospective Substudy of the NSABP B-59/GBG-96-GeparDouze Trial
Clinical Cancer Research · 2026
Improving survival outcomes of people with ABC: a global expert review and call-to-action for 2025–2035 (Goal 1)
The Breast · 2025
Community-Based Pilot Study of Chlamydia trachomatis and Neisseria gonorrhoeae Urogenital Infections Among Young Adults in the North and the Central Coast of Portugal
Medicina · 2025
Assessment of competencies of clinical research professionals and proposals to improve clinical research in Portugal
Frontiers in Pharmacology · 2025
Consensus Building Using Modified Delphi Panel and Nominal Group Techniques for Social Prescribing Intervention in Patients With Type 2 Diabetes Mellitus
Health & Social Care in the Community · 2025
Optimization of HPV-positive women triage with p16/Ki67 dual staining cytology in an organized cervical cancer screening program in the center region of Portugal
European Journal of Obstetrics & Gynecology and Reproductive Biology · 2024
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer
Annals of Oncology · 2024
180O IMpassion132 double-blind randomised phase III trial of chemotherapy (CT) ± atezolizumab (atezo) for early-relapsing unresectable locally advanced or metastatic triple-negative breast cancer (aTNBC)
ESMO Open · 2024
Breast Cancer Assistance Journey From the Perspective of the Public Healthcare Service of Rio Grande Do Sul
Jornal de Assistência Farmacêutica e Farmacoeconomia · 2024
Estimating Public Economic Gains from Early Breast Cancer and Curative Treatment: A Case Study in Human Epidermal Growth Factor Receptor (HER-2) Positive Targeted Therapies
Oncology and Therapy · 2024
Chlamydial and Gonococcal Genital Infections: A Narrative Review
Journal of Personalized Medicine · 2023
Screening for diminished ovarian reserve in Portugal: a cost-saving answer to shorten the fertility journey
Journal of Comparative Effectiveness Research · 2023